The need for cell lines from diverse ethnic backgrounds for prostate cancer research

Badal, Simone; Campbell, Kerry S.; Valentine, Henkel; Ragin, Camille

doi:10.1038/s41585-019-0234-y

Cited by 11 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of these three PCa cell lines were the springboard for an additional 197 sub‐cell lines of which 95% of them are from MEA as observed from the American Type Culture Collection website. Furthermore, 97% of the PCa cell lines available to researchers globally from main suppliers, ATCC, Sigma and European Collection of Authenticated Cell Cultures (ECACC) are from MEA …”

Section: Causes For Prostate Cancer Disparitiesmentioning

confidence: 99%

Disparities in prostate cancer incidence and mortality rates: Solvable or not?

et al. 2019

Self Cite

View full text Add to dashboard Cite

Prostate cancer (PCa) is recognized as a disease possessing not only great variation in its geographic and racial distribution but also tremendous variation in its potential to cause morbidity and death and it, therefore, ought not to be considered a homogenous disease entity. Morbidity and death from PCa are disproportionately higher in men of African ancestry (MAA) who are generally observed to have more aggressive disease and worse outcomes following treatment compared to men of European ancestry (MEA). The higher rates of PCa among MAA relative to MEA appear to be multifactorial and related to inherent differences in biological aggressiveness; a continued lack of awareness of the disease and methods of prevention; a lower prevalence of screen‐detected PCa; comparatively lower access to quality healthcare as well as systemic and institutionalized disparities in the administration of optimal care to MAA in developed countries such as the United States of America where high‐quality care is available. Even when access to quality healthcare is assured in equal access settings, it appears that MAA still have worse outcomes after PCa treatment stage‐for‐stage and grade‐for‐grade compared to MEA, suggesting that, inherent racial, ethnic and biological differences are paramount in predicting poor outcomes. This review has explored the different contributing factors to the current disparities in PCa incidence and mortality rates with emphasis on the incongruence in how research has been conducted in understanding the disease towards developing therapies.

show abstract

Section: Causes For Prostate Cancer Disparitiesmentioning

confidence: 99%

Disparities in prostate cancer incidence and mortality rates: Solvable or not?

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, this methodology could also be used to immortalize patient-derived prostate cancer cells from patients with diverse genetic ancestry, which is a major limitation of the existing PCa cell line collection. Such cell lines could potentially serve as cellular models to help address PCa disparities [31,32].…”

Section: Discussionmentioning

confidence: 99%

Immortalization of human primary prostate epithelial cells via CRISPR inactivation of the CDKN2A locus and expression of telomerase

Zhao¹,

Fowle²,

Valentine

et al. 2020

Prostate Cancer Prostatic Dis

Self Cite

View full text Add to dashboard Cite

Background Immortalization of primary prostate epithelial cells (PrEC) with just hTERT expression is particularly inefficient in the absence of DNA tumor viral proteins or p16 INK4A knockdown. Materials and methods Here, we describe the establishment of immortalized normal prostate epithelial cell line models using CRISPR technology to inactivate the CDKN2A locus concomitantly with ectopic expression of an hTERT transgene. Results Using this approach, we have obtained immortal cell clones that exhibit fundamental characteristics of normal cells, including diploid genomes, near normal karyotypes, normal p53 and pRB cell responses, the ability to form non-invasive spheroids, and a non-transformed phenotype. Based on marker expression, these clones are of basal cell origin. Conclusions Use of this approach resulted in the immortalization of independent clones of PrEC that retained normal characteristics, were stable, and non-transformed. Thus, this approach could be used for the immortalization of normal primary prostate cells. This technique could also be useful for establishing cell lines from prostate tumor tissues of different tumor grades and/or from patients of diverse ethnicities to generate cell line models that facilitate the study of the molecular basis of disease disparity.

show abstract

“…This disparity is not unique to BCa. Prostate cancer (PCa), which is more prevalent among men of African ancestry (MAA) than any other race, has disproportionally more prostate cell lines derived from men of European ancestry supplied by the ATCC, ECACC, and Sigma-Aldrich with 97% of the 32 listed cell lines being of European origin [9].…”

Section: Preclinical Models As Instruments For Investigating Breast C...mentioning

confidence: 99%

Racial disparities in breast cancer preclinical and clinical models

et al. 2022

Self Cite

View full text Add to dashboard Cite

Breast cancer (BCa) has long been a health burden to women across the globe. However, the burden is not equally carried across races. Though the manifestation and behavior of BCa differs among racial groups, the racial representation of models used in preclinical trials and clinical trial participants lacks this heterogeneity. Women of African Ancestry (WAA) are disproportionately afflicted by having an increased risk of developing BCas that are more aggressive in nature, and consequently suffer from poorer outcomes relative to women of European ancestry (WEA). Notwithstanding this, one of the most commonly used tools in studying BCa, cell lines, exhibit a sizeable gap in cell line derivatives of WEA relative to WAA. In this review, we summarize the available BCa cell lines grouped by race by major suppliers, American Type Culture Collection (ATCC) and the European Collection of Authenticated Cell Cultures (ECACC). Next, examined the enrollment of WAA in clinical trials for BCa. Of the cell lines found provided by ATCC and ECACC, those derived from WEA constituted approximately 80% and 94%, respectively. The disparity is mirrored in clinical trial enrollment where, on average, WEA made up more than 70% of participants in trials found where ancestry information was provided. As both experimental models and clinical trial participants primarily consist of WEA, results may have poorer translatability toward other races. This highlights the need for greater racial diversity at the preclinical and clinical levels to more accurately represent the population and strengthen the translatability of results.

show abstract

The need for cell lines from diverse ethnic backgrounds for prostate cancer research

Cited by 11 publications

References 9 publications

Disparities in prostate cancer incidence and mortality rates: Solvable or not?

Disparities in prostate cancer incidence and mortality rates: Solvable or not?

Immortalization of human primary prostate epithelial cells via CRISPR inactivation of the CDKN2A locus and expression of telomerase

Racial disparities in breast cancer preclinical and clinical models

Contact Info

Product

Resources

About